Gastroparesis Clinical Trial
Official title:
Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
The purpose of this research is to determine if temporary gastric electrical stimulation will help improve symptoms of gastroparesis (abnormal stomach emptying). We hypothesize that when the device is ON, Gastrointestinal symptoms will decrease by at least 50% from baseline.
Status | Completed |
Enrollment | 58 |
Est. completion date | November 2007 |
Est. primary completion date | October 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Sex: Male of Female - Age Range: 18 to 70 inclusive - Patients with GP of diabetic, surgically related or idiopathic etiology. - Symptoms of GP for >/= 1 year. - Refractory or intolerant to antiemetic drug classes (antihistamines and phenothiazines, serotonin receptor antagonists, dopamine receptor antagonists) - Chronic vomiting and/or nausea with 7 or more episodes per week for either symptom irrespective of GET values. - The patient is willing and able to provide informed consent. - The patient is willing and able to return for required follow-up visits. Exclusion Criteria: - Patients < 18 or >70 years in age. - Patients with an active infection of any kind. - Patients who the investigator determines are not candidates for endoscopic procedures. - Women who are pregnant - Inability or unwillingness to provide informed consent - Unwilling or unable to return for required follow-up visits and examinations. - Patients who are currently enrolled in another investigation of a medical device or drug. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Mississippi Medical Center | Jackson | Mississippi |
Lead Sponsor | Collaborator |
---|---|
University of Mississippi Medical Center | Medtronic |
United States,
Abell TL, Johnson WD, Kedar A, Runnels JM, Thompson J, Weeks ES, Minocha A, Griswold ME. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointest Endosc. 2011 Sep; — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Symptom of Vomiting Associated With Gastroparesis | Likert Scale 0-4 (low-high) using a patient reported outcomes tool | Study Day 0 (Baseline), Day 3, Day 7 | No |
Primary | Symptom of Nausea Associated With Gastroparesis | Likert Scale 0-4 (low-high) using a patient reported outcomes tool | Study Day 0 (Baseline), Day 3, Day 7 | No |
Primary | Symptom of Gastric Emptying Time (GET) Associated With Gastroparesis | Transit time of a radio-labeled meal through the stomach, measured by scintigraphy for %contents remaining in the stomach at 1 hour, 2 hours, and 4 hours. GET measures were obtained at baseline, during the period allowed for 'washout', and on the final study day. | Study Day 0 (Baseline), Day 4, Day 8 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03941288 -
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
|
Phase 2 | |
Terminated |
NCT03285308 -
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
|
Phase 3 | |
Completed |
NCT00733551 -
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.
|
Phase 1 | |
Completed |
NCT01650714 -
Endoscopic Full Thickness Biopsy, Gastric Wall.
|
N/A | |
Completed |
NCT01452815 -
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT01039974 -
GSK962040 Drug-drug Interaction Study With Ketoconazole
|
Phase 1 | |
Terminated |
NCT04844190 -
Use of EndoFLIP and Manometry Prior to G-POEM
|
N/A | |
Enrolling by invitation |
NCT06215547 -
Medtronic Enterra II Neurostimulator
|
N/A | |
Completed |
NCT04026997 -
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT00562848 -
A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040
|
Phase 1 | |
Enrolling by invitation |
NCT04207996 -
Vagus Nerve Response in Gastroparesis Patients
|
||
Completed |
NCT04607304 -
ABCA2 GIRMS Analytical Validation Clinical Performance Study
|
N/A | |
Recruiting |
NCT06068114 -
Gastric Pathophysiology in Diabetes
|
||
Completed |
NCT03259841 -
Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
|
||
Active, not recruiting |
NCT04300127 -
Pioglitazone for Idiopathic Gastroparesis
|
Early Phase 1 | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Terminated |
NCT04635306 -
13C-Spirulina Nitrogen Content GEBT Study
|
N/A | |
Withdrawn |
NCT02420925 -
Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis
|
N/A | |
Recruiting |
NCT00777439 -
Domperidone for Refractory Gastrointestinal Disorders
|
N/A | |
Terminated |
NCT00760461 -
Domperidone in Refractory Gastroparesis
|
Phase 2 |